Teva Gets Appeals Court to Review $10 Billion Kickback Dispute

Teva Pharmaceuticals USA Inc. convinced the First Circuit to review whether the government’s suit alleging a kickback scheme to generate prescriptions for the company’s multiple sclerosis drug Copaxone can proceed.

Immediate review of a federal district court decision is in order, a three-judge panel for the US Court of Appeals for the First Circuit said in a Nov. 17 judgment.

The government says the company violated the False Claims Act by paying $300 million to charitable foundations to increase prescriptions. The US District Court for the District of Massachusetts denied Teva summary judgment July 14.

Teva—which says it faces a ...